This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (125)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

An Effective Antiemetic in Cancer Chemotherapy

Stephen B. Strum, MD; Jonathan E. McDermed, PharmD; Richard W. Opfell, MD; Laraine P. Riech, PharmD

JAMA. 1982;247(19):2683-2686.

Abstract
An open-label clinical trial was conducted to test the safety and efficacy of intravenous metoclopramide monohydrochloride in preventing chemotherapy-induced nausea and vomiting. Thirty-eight patients received a total of 83 assessable courses of chemotherapy with cisplatin alone or in combination with other cytotoxic agents. In 19 of 38 patients (50%) or 40 of 83 courses (48%, nausea or vomiting did not occur ("total protection") and in six of 38 patients (16%) or 19 of 83 courses (23%), emesis occurred one or two times ("major protection"). Thus, 25 of 38 patients (66%) receiving 59 of 83 courses (71%) of cisplatin-containing chemotherapy attained either total or major antiemetic protection with metoclopramide. In those patients who received multiple courses of chemotherapy, antiemetic protection afforded by metoclopramide remained unabated. At this dosage, the drug was well tolerated with minimal side effects. Intravenous metoclopramide is consistently effective in preventing emesis associated with cisplatin when used either alone or in combination with other cancer chemotherapy agents that are in themselves emetogenic.

(JAMA 1982;247:2683-2686)

Author Affiliations
From the Departments of Medicine (Dr Strum) and Pharmacy (Drs McDermed and Riech), Brotman Medical Center, Culver City, Calif; the Hematology-Oncology Medical Group of Orange County, Tustin, Calif (Dr Opfell); the Department of Medicine, Section of Hematology, Los Angeles County-University of Southern California Medical Center, Los Angeles, and the School of Pharmacy, University of Southern California, Los Angeles (Drs McDermed and Riech).

Footnotes
Reprint requests to 9808 Venice Blvd, Suite 206, Culver City, CA 90230 (Dr Strum).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravenous administration of metoclopramide by 2 min bolus vs 15 min infusion: does it affect the improvement of headache while reducing the side effects?
Parlak et al.
Postgrad. Med. J. 2007;83:664-668.
ABSTRACT | FULL TEXT  

Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla et al.
JCO 1999;17:2971-2971.
FULL TEXT  

Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting: A Multicenter, Randomized, Double-Blind, Crossover Study
De Mulder et al.
ANN INTERN MED 1990;113:834-840.
ABSTRACT  

Metoclopramide-Induced Movement Disorders: Clinical Findings With a Review of the Literature
Miller and Jankovic
Arch Intern Med 1989;149:2486-2492.
ABSTRACT  

Optimizing Metoclopramide Control of Cisplatin-Induced Emesis
MEYER et al.
ANN INTERN MED 1984;100:393-395.
ABSTRACT